To investigate the impact of 68 Gallium prostate-specific membrane antigen (68 Ga-PSMA) tracers on the management of prostate cancer patients with biochemical recurrence (BCR) by systematical review and meta-analysis. <\/p>\n
We performed a literature search on PubMed, Embase, and Web of Science databases up to October 29, 2019. We included studies that reported the proportion of management change after 68 Ga-PSMA tracers in patients with BCR. We used the Quality Assessment of Diagnostic Accuracy Studies-2 tool to evaluate the quality of the included studies. The proportion of management changes were pooled using a random-effects model. Subgroup analyses and meta-regression analyses were performed to explore the source of heterogeneity. Sankey diagram was used for displaying the treatment change from the before to after 68 Ga-PSMA tracers.<\/p>\n
We included 20 eligible studies (2,026 patients). The pooled of management change occurred in 53% (95% confidence interval (CI), 46-60%) of patients with BCR and 51% (95% CI, 34%-67%) in early BCR group (prostate-specific antigen (PSA) < 0.5 ng\/mL). The pooled PET-positive in patients with BCR was 68% (95%CI, 59%-78%). Fourteen studies reported the management change, with most changes being intermodality (42% vs 17% in intramodality).<\/p>\n
The 68 Ga-PSMA tracers can alter the management of more than half of prostate cancer patients with BCR, as well as in the early BCR patients. The 68 Ga-PSMA tracers might be used to guide the individualised treatment in patients with BCR, particularly in the early recurrence patients.<\/p>\n
BJU international. 2020 Sep 26 [Epub ahead of print]<\/p>\n
Wei Diao, Yuan Cao, Dunyan Su, Zhiyun Jia<\/p>\n
Department of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu, PR China., Huaxi MR Research Center, Department of Radiology, West China Hospital of Sichuan University, Chengdu, PR China.<\/p>\n
PubMed http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32979229<\/a><\/p>\n <\/p>\n Here is the original post: To investigate the impact of 68 Gallium prostate-specific membrane antigen (68 Ga-PSMA) tracers on the management of prostate cancer patients with biochemical recurrence (BCR) by systematical review and meta-analysis. Continue reading
\n68 Ga-prostate-specific membrane antigen tracers can alter the management of more than half of prostate cancer patients with biochemical recurrence. -...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"